FHIR IG analytics| Package | de.medizininformatikinitiative.kerndatensatz.mtb |
| Resource Type | MedicationStatement |
| Id | MedicationStatement-MII-EXA-MTB-Systemische-Therapie-Medication-3.json |
| FHIR Version | R4 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
English
Generated Narrative: MedicationStatement MII-EXA-MTB-Systemische-Therapie-Medication-3
Profiles: MII PR MTB Systemtherapie Medication Statement, https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemische-therapie-medication-statement|2027.0.0-ballot.1
partOf: Procedure Zytostatische Chemotherapie, Immuntherapie und antiretrovirale Therapie
status: Completed
statusReason: E
medication: MIRVETUXIMAB SORAVTANSINE
subject: Kim Musterperson (no stated gender), DoB: 1956-03-14
effective: 2023-08-07 --> 2023-08-07
note:
07.08.2023 Z3 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
dosage
timing: Events: 2023-08-07
DoseAndRates
Dose[x] 6 mg/kg KG (Details: UCUM codemg/kg{KG} = 'mg/kg{KG}')
German
Generated Narrative: MedicationStatement MII-EXA-MTB-Systemische-Therapie-Medication-3
Profiles: MII PR MTB Systemtherapie Medication Statement, https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemische-therapie-medication-statement|2027.0.0-ballot.1
partOf: Procedure Zytostatische Chemotherapie, Immuntherapie und antiretrovirale Therapie
status: Completed
statusReason: E
medication: MIRVETUXIMAB SORAVTANSINE
subject: Kim Musterperson (no stated gender), DoB: 1956-03-14
effective: 2023-08-07 --> 2023-08-07
note:
07.08.2023 Z3 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
dosage
timing: Events: 2023-08-07
DoseAndRates
Dose[x] 6 mg/kg KG (Details: UCUM codemg/kg{KG} = 'mg/kg{KG}')
{
"resourceType": "MedicationStatement",
"id": "MII-EXA-MTB-Systemische-Therapie-Medication-3",
"meta": {
"profile": [
"https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement",
"https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemische-therapie-medication-statement|2027.0.0-ballot.1"
]
},
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"basedOn": [
{
"reference": "MedicationRequest/mii-exa-mtb-medication-request-mirvetuximab"
}
],
"partOf": [
{
"reference": "Procedure/MII-EXA-MTB-Systemische-Therapie-1"
}
],
"status": "completed",
"statusReason": [
{
"coding": [
{
"code": "E"
}
]
}
],
"medicationCodeableConcept": {
"coding": [
{
"system": "http://fdasis.nlm.nih.gov",
"code": "98DE7VN88D",
"display": "MIRVETUXIMAB SORAVTANSINE"
},
{
"system": "http://fhir.de/CodeSystem/bfarm/atc",
"version": "2025",
"code": "L01FX26",
"display": "Mirvetuximab soravtansin"
}
]
},
"subject": {
"reference": "Patient/PatientKimMusterperson"
},
"effectivePeriod": {
"start": "2023-08-07",
"end": "2023-08-07"
},
"note": [
{
"text": "07.08.2023 Z3 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22"
}
],
"dosage": [
{
"timing": {
"event": [
"2023-08-07"
]
},
"doseAndRate": [
{
"doseQuantity": {
"value": 6,
"unit": "mg/kg KG",
"system": "http://unitsofmeasure.org",
"code": "mg/kg{KG}"
}
}
]
}
]
}